ReviewNeurology2025
Neuroimaging in Children With Inherited Metabolic Epilepsies.
Review in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A systematic approach to MR spectroscopy of the brain: Indications, protocol, metabolites, and spectral analysis in neurologic diseases.The neuroradiology journal · 2026Review
- Neurodevelopmental disorders in children: the role of MRI in early detection and intervention planning.Frontiers in neuroscience · 2026Review
- Central Dysmyelination in SSADH-Deficient Humans and Mice.Annals of clinical and translational neurology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inherited metabolic epilepsies (IMEs) represent inherited metabolic disorders in which seizures, various in types and typically intractable, are one of the predominant manifestations and primary determinants of the overall outcome. A metabolic etiology should be suspected in any case of refractory seizures stemming from an undetermined cause. While the occurrence rate of individual IMEs is rare, their cumulative prevalence is high enough to pose a significant clinical challenge. Concurrently with genetic and metabolic tests, neuroimaging is considered part of the first tier of their investigation, attained with an aim to affirm or counter the phenotype. It may be normal or nonspecific; however, as described by this overview, there is an appreciable number of IMEs associated with distinct MRI or magnetic resonance spectroscopy patterns. Apart from narrowing or supporting their diagnoses, these neuroimaging patterns may serve as biomarkers to monitor treatment efficacy and outcome. Other advanced modalities and techniques, such as PET, fMRI, diffusion tensor imaging, MRI g-ratio mapping, and functional near-infrared spectroscopy, broaden our insights relating to their pathophysiology, clinical course, targeted treatment development, and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.